Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy.
Parkinson’s disease
cerebrospinal fluid
chromogranin A
multiple system atrophy
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
22 Jan 2021
22 Jan 2021
Historique:
received:
21
12
2020
revised:
11
01
2021
accepted:
19
01
2021
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
28
1
2021
Statut:
epublish
Résumé
Chromogranin A (CgA) and other peptides from the chromogranin-secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson's disease (PD). We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent. In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L; We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.
Sections du résumé
BACKGROUND
BACKGROUND
Chromogranin A (CgA) and other peptides from the chromogranin-secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson's disease (PD).
METHODS
METHODS
We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent.
RESULTS
RESULTS
In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L;
CONCLUSIONS
CONCLUSIONS
We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.
Identifiants
pubmed: 33499181
pii: brainsci11020141
doi: 10.3390/brainsci11020141
pmc: PMC7912438
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : Institutional Support 2020 - conceptual development of a research organization (FNOl, 0098892.)
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : European Regional Development Fund - Project ENOCH (No. Z.02.1.01/0.0/0.0/16_019/0000868)
Références
Clin Proteomics. 2020 Jun 5;17:21
pubmed: 32518535
Acta Neurol Scand. 2017 Oct;136(4):360-364
pubmed: 28185258
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Cell Mol Neurobiol. 2003 Oct;23(4-5):519-26
pubmed: 14514012
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Cell Mol Life Sci. 2010 Mar;67(6):861-74
pubmed: 19943077
Eur J Clin Invest. 1998 Jun;28(6):431-40
pubmed: 9693933
Ann Surg Oncol. 2010 Sep;17(9):2427-43
pubmed: 20217257
Neuroscience. 1993 Oct;56(4):999-1007
pubmed: 7904334
J Alzheimers Dis. 2020;73(4):1355-1361
pubmed: 31929170
Clin Auton Res. 2015 Oct;25(5):339-42
pubmed: 26359267
Sci Rep. 2020 Feb 12;10(1):2479
pubmed: 32051502
N Engl J Med. 2003 Mar 20;348(12):1134-49
pubmed: 12646671
J Neural Transm (Vienna). 2013 Nov;120(11):1559-63
pubmed: 23588348
Kaohsiung J Med Sci. 2019 Mar;35(3):146-150
pubmed: 30887724